Konsenzus Kitajskega združenja za klinično prehrano o prehranski podpori pri bolnikih s COVID-19
Zhen Yu1*, Ding-Ye Yu2*, Dong-Dong Huang3, Sheng Wang4, a Hu Peng5, b, Yong-Chao Liu6, c, Song-Juan Yan5, a, Hong Xu7, c, Jun-Min Wei8, Guo-Hao Wu9, Chang-Hui Wang10, d, Kai-Ying Yu11, Xiao-Wei Zhang11, Yun Yang11, Liu-Qing Yang11, Kun-Hua Wang12, Juan Kong13, Hong-Xia Xu14*, Huan-Long Qin1*, Han-Ping Shi11*. The Chinese Society for Parenteral and Enteral Nutrition, CSPEN.
1 Department of General Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University
2 Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
3 Department of Gastrointestinal Surgery, The First Affiliated Hospital, Wenzhou Medical University
4 Department of Surgical Intensive Care Unit, Shanghai Tenth People’s Hospital Affiliated to Tongji University
5 Department of Emergency Medicine, Shanghai Tenth People’s Hospital Affiliated to Tongji University
6 Department of Intensive Care Unit, Shanghai Tenth People’s Hospital Affiliated to Tongji University
7 Department of Orthopaedics, Shanghai Tenth People’s Hospital Affiliated to Tongji University
8 Department of General Surgery, Beijing Hospital, Ministry of Health
9 Department of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University
10 Department of Respiration, Shanghai Tenth People’s Hospital Affiliated to Tongji University
11 Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University
12 Department of Surgery, The First Affiliated Hospital, Kunming Medical University
13 Department of Clinical Nutrition, Shenjing Hospital, Chinese Medical University
14 Department of Clinical Nutrition, Daping Hospital, The Third Military Medical University
These authors are now working on the front line to fight COVID-19 at the following medical organizations:
a Shanghai Public Health Center
b Intensive Care Unit of Wuhan Third People’s Hospital
c Intensive Care Unit of Wuhan Jinyintan Hospital
dShanghai Center for Disease Control and Prevention
* These authors contributed equally to this study.
Han-Ping Shi, MD, PhD, FACS, Departments of Gastrointestinal Surgery / Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, No.10 Tieyi Road，Haidian Dist, Beijing 100038, China; Tel: +86-10-63926985; E-mail: firstname.lastname@example.org
Huan-Long Qin, MD, PhD, Department of General Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University, Shanghai, 200072, China E-mail: email@example.com
Hong-Xia Xu, MD, PhD, Department of Clinical Nutrition, Daping
Hospital, The Army Medical University, Changjiagnzhilu10#, Yuzhong District, Chongqing
400042, China, Tel: +86-23-68757667, Email: firstname.lastname@example.org
COVID-19 infections are a new challenge to the world. Severe patients have a significant higher morbidity and mortality compared with non-severe ones. In response, the Chinese Society for Parenteral and Enteral Nutrition (CSPEN) formulated this multidisciplinary consensus, calling on integrate medical nutrition therapy into routine care for COVID-19 infections as follows.
- Set up NST;
- Routinely investigate nutritional status;
- Provide adequate calorie at 15-30 kcal/kg/d and protein at 1.2-2.0 g/kg/d;
- Adhere to five-step model nutrition therapy;
- Reduce metabolic and inflammatory response by limiting energy, intestinal and fluid load;
- Early implement enteral nutrition, with ONS preference;
- Emphasize SPN;
- Select PN and EN formulation on individual base;
- Address life-threatening complications and comorbidities;
- Ensure the successful nutritional care.
CSPEN hopes this consensus will also help the other countries in fighting with COVID-19 infections.
Key words: COVID-19 infections; severe patients; nutrition therapy;
As of 11:00 a.m. on February 24, 2020, Chinese officials had recorded 77,262 confirmed cases of COVID-19-associated pneumonia which has been classified as non-severe and severe two categories by Nan-Shan Zhong(1), with a reported 15.7% to 25.5% of severe patients reported in the literature(1, 2), there were 12,130 to 19,702 severe patients. Compared with non-severe patients, severe patients have a higher mortality rate (8.1% vs.1.4%), a higher incidence of complications (pneumonia: 94.8% vs. 76.1%, ARDS: 15.6% vs. 11%, septic shock: 6.4% vs. 0%, acute renal injury: 2.9% vs. 0.1%), require more treatment (intravenous antibiotics: 80.3% vs. 53.2%, oseltamivir: 46.2% vs. 33.8%, systemic corticosteroids: 44.5% vs. 13.7%, mechanical ventilation: 38.7% vs. 0%, immunoglobulin: 32.9% vs. 9.3%), and are more likely to enter the ICU (19.1% vs. 2.4%)(1). This indicates that severe patients are the focus of treatments because of their poorer prognosis. These patients are also more difficult to treat, and consume more manpower, materials and financial resources. COVID-19 infections are a new challenge, and there are no evidence-based therapeutic guidelines to follow. Learning from past experiences in the treatment of influenza, HIV, MERS and SARS(3-5), and following the recommendations of the Academy of Nutrition and Dietetics supporting the integration of medical nutrition therapy into routine care for the HIV population(5), the Chinese Society for Parenteral and Enteral Nutrition (CSPEN) recently formulated a “consensus on nutrition therapy for severe patients with COVID-19 infections” in order to improve the treatment of these patients.
1. Nutrition support teams (NST)
Recommendation 1: Set up NST, which should be routinely involved in the treatment of severe patients
Due to the lack of proven specific treatments, improving immunity, controlling symptoms and providing supportive care remain the main measures for treating COVID-19 infection(6). Nutrition is the key to human immunity, and nutrition therapy should become part of the routine care and a major means for improving the outcome of patients with COVID-19 infection, especially for severe patients(7). The establishment of a NST is considered to be the most effective measure to implement nutrition therapy, which has been shown to effectively shorten the length of stay (LOS) in the hospital, LOS in the ICU and the duration of mechanical ventilation for critically-ill patients(8).
The NST, which should be comprised of clinicians, dietitians, clinical pharmacists, nurses, et al., should become a core of the multidisciplinary team that treats severe patients with COVID-19 infections. In particular, the duty of the NST is to accurately identify the patients at nutritional risk or with malnutrition, to formulate a reasonable nutrition therapy plan, and to monitor and evaluate the effects of the nutrition therapy(9, 10).
2 Nutrition diagnosis
Recommendation 2: Routinely investigate the nutritional status of severe patients and implement a three-stage nutritional diagnostic program (i.e. 1. nutritional screening, 2. nutritional assessment and 3. comprehensive investigation using any validated tools)
Obtaining an accurate diagnosis of the nutrition status is the foundation of nutrition therapy. Before initiating systematic treatment, the nutritional status of all patients with COVID-19 infection should be investigated as a routine(11). The nutrition diagnosis should be carried out step-by-step using any validated tool. Screening should be carried out first to identify “at risk” status, then the nutrition assessment should confirm the diagnosis of malnutrition and grade its severity and the third should be a comprehensive investigation of the physical, physiological and psychological effects of malnutrition (figure 1)(12). It is recommended that the NUTRIC or modified NUTRIC be used for nutrition risk screening(13-15), followed by the SGA(13, 16) or GLIM(17, 18) for nutrition assessment. Clinical observations found that compared with non-severe patients, severe patients have more underlying diseases (37.6% vs. 20.5%), more lung X-ray changes (26.65 vs. 12.5%), higher hematological abnormalities (white blood cells, lymphocytes, platelets and hemoglobin) and more functional impairments (liver function, renal function, lung function)(1, 2). Therefore, it is necessary to perform a third round of diagnosis, i.e. a comprehensive investigation analyzing malnutrition from four dimensions (energy expenditure, stress levels, inflammatory responses, and metabolic status), and also investigating the effects of malnutrition at five levels (body composition, physical fitness, organ function, psychological status, and quality of life)(19).
3. Energy and protein
Recommendation 3: The caloric intake should be 15 to 30 kcal/kg/day, the ratio of energy derived from glucose to that from lipids should be 50%-60%/40%-50%; the protein intake should be 1.2-2.5 g/kg/day, and the nonprotein calorie-to-nitrogen ratio should be 100-150 kcal:1 g.
Fever (87.9% – 98.6%), cough (59.4% – 82.0%), muscle pain and fatigue (44% – 69.6%) are the most common symptoms of hospitalized patients with the COVID-19 infection(1, 20-22). Severe patients have a higher body temperature, more severe shortness of breath, a greater likelihood of having an increased C-reactive protein level (>10 mg/L: 81.5% vs. 56.4%) and procalcitonin level (>5 ng/ml: 13.7% vs. 3.7%), higher levels of inflammatory mediators (IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, TNF) at admission(1, 20-22), and an albumin level that continues to decrease after admission(23). All the above information suggests that the energy expenditure and protein catabolism of severe patients with COVID-19 infections are higher, so their nutrition therapy should be different from that of non-severe patients, particularly with regard to the energy supply and protein content of the diet. Although the daily energy expenditure (EE) of critically-ill patients may exceed 50% of the normal resting energy expenditure (REE), which is equivalent to 36 kcal/(kg·d), studies have found that the REE of most critically-ill patients is normal, which equates to 22-25 kcal/kg/day. Because most critically-ill patients are inactive, the average REE is closer to the total daily energy expenditure (TDEE)(24). Considering the diversity of severe patients, the CSPEN recommends a broad range of energy consumption, from 62.7~125.4 kJ (15~30 kcal/kg/day). Patients with severe malnutrition, obesity, and acute phase disease (within 4 days after entering the ICU) are recommended to gradually increase their energy supply to more than 80% of the estimated energy needs within 3-7 days, starting with 62.7kJ (15 kcal/kg/day)(24-26). The protein supply is different from the hypocaloric energy supply in the acute phase in patients with severe infections, and we emphasize that the early provision of an adequate supply of protein (1.2-2.5 g/kg/day) is necessary. The calories administered to patients on mechanical ventilation can be calculated based on the carbon dioxide production (VCO2) × 8.19. It is recommended that the caloric needs be calculated using an indirect calorimetry metabolic cart system if conditions permit(24-26).
4. The five-step ladder of nutrition therapy
Recommendation 4: Nutrition therapy should adhere to the five-step ladder model, starting from nutritional counseling/dietary modification and increasing step-wise to total parenteral nutrition, following the ‘50% principle’ to ensure a smooth nutrition ladder transition.
In order to standardize the nutrition therapy for severe patients with COVID-19 infection and give full play to the significant dual potential (improving the clinical outcome and reducing costs) of nutrition therapy(27-29), the CSPEN recommends a five-step ladder nutrition therapy model which consists of 1) oral diet nutritional counseling/dietary modification, 2) oral diet plus oral nutritional supplements (ONS), 3) exclusive enteral nutrition (EEN, oral or tube feeding), 4) partial enteral nutrition (PEN) plus partial parenteral nutrition (PPN), and 5) total parenteral nutrition (TPN) (figure 2)(30), complying with the principles of diet priority, oral route priority and enteral nutrition priority.
The first step of nutrition therapy is oral diet nutritional counseling/dietary modification. Artificial nutrition (enteral nutrition, parenteral nutrition) is chosen only when the diet is insufficient; the first choice of nutrition route is the trans-oral approach, such as ONS. Tube feeding is chosen only when the oral intake is insufficient. Enteral nutrition is the first choice of artificial nutrition, and parenteral nutrition is chosen only when enteral nutrition is insufficient. If the treatment lower on the ladder cannot meet 60% of the targeted energy requirement for 2-3 days, the treatment on the next rung of the ladder should be applied. The nutrition ladder transition for severe patients, i.e. the bottom-up and top-down models in the five-steps ladder, should be switched or transitioned smoothly following the ‘50% principle’ , which means that when enteral nutrition can meet 50% of the target demand, parenteral nutrition should be gradually reduced or stopped while enteral nutrition should be gradually increased; when an oral diet can meet 50% of the target demand, enteral nutrition should be gradually reduced or stopped while the oral diet should be increased gradually; conversely, when 50% of the target demand cannot be met, the parenteral nutrition or enteral nutrition must be continued.
5. Metabolic support and inflammation regulation
Recommendation 5: Reduce the metabolic load, suppress the excessive inflammatory response, and maintain homeostasis.
Cytokine storm and hypermetabolism organ failure complex (HMOFC) are serious conditions that occur in association with many infectious or non-infectious diseases such as MERS, sepsis, and malignancy(31-34). Cytokine storm and HMOFC have also been documented in some patients with the new coronavirus infection, and were important contributors to the patients’ deaths. Severe patients have more severe stress reactions, more significant metabolic disorders, higher levels of inflammatory factors, and faster disease changes(1, 20, 22), highlighting the importance of maintaining metabolic homeostasis and regulating inflammatory responses. In addition to traditional antiviral therapy and glucocorticoid therapy, severe patients also need metabolic support and inflammation regulation therapy as follows: (1) Reduce the energy load, providing 10-15 kcal/kg/d or <30%-50% of the target requirement during the severe acute phase, in cases with hemodynamic instability, ARDS, etc.(35-37), (2) Increase the protein and branched-chain amino acids (BCAA) supply, using supplements if necessary, and inhibit catabolism. It is recommended that 1.5-2.0 g (1.8-3.0 g free amino acids)/kg/d(24, 36) be provided to such patients, and the BCAA ratio should be increased to 35%, which can not only significantly inhibit muscle breakdown(38), but also improve insulin resistance(39) and enhance the efficacy of interferon(40), (3) Inhibit excessive inflammation and regulate immune function. The use of N-3 fatty acids in critically-ill patients can reduce the risk of death, infection, and hospital LOS(41), (4) Inhibition of free radicals to reduce peroxidation damage. The intravenous injection of vitamin C at 3~10 g/d significantly reduced mortality and shortened the use of booster drugs and the need for a ventilator in critically-ill patients(42). The administration of vitamin C may become a standard treatment for patients with sepsis(43) and is effective for patients with virus-associated ARDS(44), (5) Reduce the intestinal load by limiting volume overload and enhancing bowel movement, inhibition of endotoxin release into the bloodstream. Apply tropical enteral nutrition early, and add dietary fiber and prebiotics on an individual basis. (6) Reduce fluid load, especially I.V. fluid.
6. Enteral nutrition
Recommendation 6: Early implementation of enteral nutrition (EN), with an emphasis on ONS.
Gastrointestinal dysfunction in patients with COVID-19 infection is relatively rare, and the incidence of diarrhea and vomiting being only 3.7% and 5.0%, respectively(1). It is thus possible to implement enteral nutrition for most COVID-19 patients. Enteral nutrition should be implemented according to the individual’s condition, gradually transitioning from a predigested formula to a whole protein formula or homogenate preparations. Patients with gastrointestinal dyspepsia may benefit from the administration of short peptide or amino acid formulas. Early enteral nutrition (EEN) can regulate the balance of Th17/Treg cells, inhibit the IL-23/IL-17 axis, reduce the clinical severity of sepsis(45), and reduce infectious complications in critically-ill patients. However, it is recommended that EN be delayed for critically-ill patients with uncontrolled shock, uncontrolled hypoxemia and acidosis, uncontrolled upper GI bleeding, gastric aspiration >500 ml/6 h, bowel ischemia, bowel obstruction, abdominal compartment syndrome, or a high-output fistula without distal feeding access(46). When EEN was initiated within 48 hours of admission to the ICU, there was a significant improvement in the clinical prognosis compared to when it was initiated after 48 hours(46). EN is safe and effective in patients with severe pancreatitis within 24-48 hours, which provides more benefit than delayed enteral nutrition(47, 48). ONS should be given if the oral diet fails to achieve 60% of the energy and protein targets, with a recommended daily supplementation of 400-600 kcal in addition to the oral diet(49, 50). Proper EN, such as ONS, shortens the length of hospitalization, reduces the episode costs, and reduces the 30-day readmission risk(27). However, EN alone is typically unable to fulfill the target requirements for critically-ill patients. A multi-institutional, prospective study of 3,390 mechanically-ventilated patients at 201 centers from 26 countries found that EN was started on average 38.8 hours after admission. The majority (74.0%) of patients did not meet at least 80% of their target energy, with only 61.2% of the energy and 57.6% of the protein prescribed being delivered to patients(51). Critically-ill patients prescribed enteral nutrition alone have a higher risk of malnutrition (OR = 3.77, 95% CI = 2.71-5.24)(9). Combining enteral nutrition and parenteral nutrition is more likely to achieve target requirements(52), reduce infectious complications, reduce 30 day death(52, 53), and improve the patient’s nutritional status and clinical outcomes(52, 53).
7. Parenteral nutrition
Recommendation 7: Fully understand the importance of parenteral nutrition, emphasize supplemental parenteral nutrition (SPN), and consider commercial multi-chamber bags first.
Recent studies have found that the vast majority of critically-ill patients do not meet the 60% target requirement(54). Similar to other diseases, the severe patients with COVID-19 infections may be unable to meet the target nutritional requirements via an oral diet and/or enteral nutrition. Even worse, many widely-used antiviral drugs have severe adverse gastrointestinal effects, which may prevent patients from eating or digesting oral nutrition. A negative energy balance (energy deficit) has been shown to increase infectious complications, the length of hospital stay, and duration of time on a ventilator(52, 54), so parenteral nutrition has become a necessary support for severe patients with COVID-19 infections(55). When enteral nutrition cannot meet 60% of the target energy and protein within 48-72 hours, it is recommended that SPN be provided as soon as possible, because it can improve the clinical outcomes and decrease the medical costs(56-59). An all-in-one formula is recommended over multi-bottle infusions, as commercial multi-chamber bags have many advantages(60, 61) although some patients need an individualized, all-in-one parenteral nutrition formula(62). PN is more likely to improve the patient’s nutritional status, and also has a positive effect on disease treatment and successful weaning from a ventilator, helping patients to survive the dangerous acute infection period and promoting their rehabilitation(55, 63). However, it is necessary to monitor the metabolic status frequently and adjust the PN prescription to prevent overfeeding(64).
8. Formulation selection
Recommendation 8: Increase the proportion of lipids and amino acids in the PN while reducing the proportion of glucose. Preferentially, choose medium- and long-chain lipid emulsions, and increase the omega-3 and omega-9 fatty acid content. Choose general formulas for EN, while disease-specific formulas are recommended for patients with coexisting conditions.
The PN formula for severe patients with COVID-19 infections requires an increase in the proportion of lipids and amino acids, and a reduction in the proportion of glucose. Preference should be given to medium- and long-chain lipid emulsions, and there should be an increase in omega-3 and omega-9 fatty acids. Increasing the proportion of fat in the PN solution may increase the success rate of weaning from the ventilator and shorten the mechanical ventilation time. The inclusion of omega-3 fatty acids in PN can significantly decrease the production of inflammatory factors, triglyceride levels, and liver enzymes(65), improve gas exchange, reduce infectious complications, shorten the length of total hospitalization and reduce the ICU stay(66). In addition, the use of PN has shown significant benefits pharmacoeconomically(67). The immune-neutral effects of ω-6:ω-3 = 2.1: 1 can prolong the survival time of transplanted organs, and may similarly protect native organs from stress(68). The above studies suggest that omega-3 fatty acids are beneficial for preventing cytokine storm and HMOFC in severe patients with COVID-19 infections. The addition of alpha-tocopherol can enhance the anti-inflammatory effects of omega-3 fatty acids(69). Omega-9 fatty acids have immune-neutral and low-inflammatory properties, and are rich in alpha-tocopherol. Long-term use of omega-9 fatty acids can increase oxidized glutathione and protect the liver function(70). The injection of antioxidant-free amino acids may be safer for severe patients with COVID-19 infections, and should be considered for those unable to sustain a sufficient intake via other means(71).
General EN formulations are preferred over disease-specific formations except in those with comorbid or coexisting diseases. For those with diabetes, diabetes-specific food for special medical purpose (FSMP) is recommended. FSMP with a low sugar and high fat content may be a better choice for diabetic patients with respiratory insufficiency. Tumor-specific FSMP may benefit more for patients with advanced cancer(72, 73). Immune-modulated nutritional preparations can theoretically promote the recovery of critically-ill patients(74-77). Dietary fiber, prebiotics, probiotics, etc. have certain effects, including the induction of flatulence, diarrhea, and a microecological balance, they could be used on an individualized consideration, especially for probiotics. Homogenate diets from dark green vegetables, fruits, and beans, are rich of antioxidants such as vitamin C, vitamin E, carotenoids, and selenium can reduce oxidative stress-related damage(78).
9. Nutrition therapy for comorbidities
Recommendation 9: Attention should be paid to nutrition therapy that can address life-threatening complications and comorbidities.
According to the report by Nan-Shan Zhong et al.(1), hypertension (14.9%) and diabetes (7.4%) are the two most common comorbidities. Pneumonia (79.1%) and ARDS (3.4%) are the two most common complications. All other conditions and complications were found in fewer than 3% of cases. However, compared to non-severe patients, severe patients with COVID-19 infections had an older average age (52 yr. vs. 45 yr., P<0.001), more comorbidities (hypertension: 23.7% vs. 13.3%, diabetes: 6.2% vs. 5.7%), and a higher incidence of complications (pneumonia: 94.8% vs. 76.1%, ARDS: 15.6% vs. 1.1%). These observations emphasize that providing nutrition therapy targeting these comorbidities and complications is of great importance in severe patients with COVID-19 infections. The specific indications for these conditions are described below:
- ARDS: Clinical observations have shown that ARDS is the leading cause of death in severe patients with COVID-19 infections. Nutrition therapy for ARDS follows the general principles of metabolic support and inflammation regulation described above, including inhibiting the inflammatory response, reducing the metabolic load and inhibiting catabolism. It is essential to perform trophic EN(79-81), controlled underfeeding of PN, to provide sufficient BCAA(82), moderate addition of omega-3 fatty acids, and to include dietary fiber. A subgroup analysis within a meta-analysis showed that moderate underfeeding of EN reduced the overall mortality in patients with acute respiratory failure(80). Compared to septic shock patients without EN or those receiving ≥600 kcal/d EN, those receiving EN <600 kcal/d starting within 48 hours of admission had a significantly reduced mechanical ventilation time and ICU hospital stay(81). Short-term (2 consecutive days) oral intake of 14.4 g BCAA significantly improved the respiratory quotient (RQ), while continuous oral intake for 30 days significantly improved the handgrip strength without increasing the oxygen consumption (VO2) and heat production(82). Supplementation of omega-3 fatty acids significantly and continuously improved the PaO2/FiO2 ratio in ARDS patients, and there was also a tendency toward a reduced duration of mechanical ventilation and ICU hospital stay(83).
- Hypoproteinemia: It has been reported that 83% of severe patients with COVID-19 infections have elevated C-reactive protein levels(84) and 50% of patients had decreased albumin level at admission, with a continuous drop after admission(23). Albumin has a variety of physiological functions, such as maintaining the colloid osmotic pressure, serving as a carrier for a variety of biological substances, scavenging free radicals, being an antioxidant, and anti-platelet aggregation. Hypoalbuminemia may indicate (1) poor nutritional status, (2) reduced antioxidant, anti-free radical, and detoxification capabilities, and (3) severe acute inflammation(85), all of which lead to a poor clinical prognosis. Hypoalbuminemia also alters the pharmacokinetics and pharmacodynamics of albumin-carried drugs, including antibiotics(86, 87). Intravenous albumin infusion has limited efficacy and is associated with many adverse reactions, hence it should be as per individual condition, but not be the first choice of hypoalbuminemia treatment(88). Rather, administering EEN rich in protein provides a better solution(89).
- Diabetes/Hyperglycemia: Hyperglycemia is a well-known indication of a poor clinical prognosis(90). High glycemic variation (mean amplitude of glycemic excursions (MAGE) >65 mg/dL) within 24 hours of ICU admission is an independent risk factor for an increased 30-day mortality(91). Therefore, the management of blood glucose in critically-ill patients, especially those with diabetes, includes two aspects: blood glucose control and blood glucose stabilization(92). The American Academy of Internal Medicine recommends that the blood glucose of ICU patients be maintained at 7.8-11.1 mmol/L (140-200 mg/dL) but not less than 7.8 mmol/L (<140 mg/dL) with insulin administration(90). Hypoglycemia is also an important cause of death; therefore, the blood glucose levels should be continuously and dynamically monitored to avoid dramatic fluctuations(92, 93).
The average blood glucose concentration and glycemic variability of diabetic critically-ill patients have not been found to have an association with ICU death, which is different from patients without diabetes. Nonetheless, hypoglycemia, with a cutoff point of ≤2.2 mmol/L, is related to ICU death for both non-diabetics and diabetics(93). The cut-off points for low glucose are different for non-diabetics and diabetics, namely 4.9 mmol/L and 3.5 mmol/L, respectively(93).
Nutritious formula with low glucose and high-fat content that is rich in fiber helps control blood glucose, reduce insulin requirements, and lowers the risk of hypoglycemia. Nutrition therapy prescribed by a registered dietitian (RD) plays an important role in diabetes management(94).
(4) Hypertension: Hypertension being the most common comorbidity in patients with COVID-19 infections may be due to its high incidence among the population, rather than being condition-specific. Although the rate of hypertension in severe patients with COVID-19 infections is higher than that of non-severe patients, it may be related to the older age of these patients rather than the disease status. The provision of nutrition therapy for hypertension in severe patients with COVID-19 infections should follow the principles of nutrition therapy for general hypertension patients. This may include but not limited to discarding eating habits that make the subject prone to hypertension, increasing physical activity and increasing plant-based food intake, taking supplemental calcium, magnesium, potassium, folic acid and vitamin D, and reducing homocysteine levels, sodium intake and alcohol consumption(95-97). Nutrition therapy by RD is essential in the management of hypertension.
- Nutritional care
Recommendation 10: A prerequisite for ensuring the successful implementation of nutrition therapy is to rapidly detect nutritional deficiencies and treat complications. Attaching great importance to nutritional care and management.
- Management of PN infusion
Severe patients with COVID-19 infections usually have a central venous catheter or central venous catheterization via peripheral venipuncture, which can administer fluids at a speed less than 200 mL/h. An intravenous infusion pump is recommended for providing PN. Severe patients with COVID-19 infections are often older and have weaker immunity, and are at high risk for catheter-related bloodstream infections (CR-BSI). A continuous quality improvement plan is an effective measure to reduce CR-BSI(98-100). Such plans should include: (1) paying attention to hand hygiene, (2) avoiding unnecessary intubation, (3) ensuring that there are completely sterile barrier precautions when inserting a tube, (4) performing subclavian vein catheterization, (5) sterilizing skin using 2% chlorhexidine ethanol solution, (6) use a chlorhexidine-containing device to secure the catheter, (7) change wet or loose dressings in a timely manner, (8) remove the catheter as early as possible, (9) use a commercial multi-chamber bag, (10) if there is local redness, swelling, heat, pain or fever of unknown origin, CR-BSI should be considered. The catheter should be removed and a catheter tip culture should be performed. Advanced patient age and long-term retention are independent risk factors for CR-BSI(101).
- Management of tube feeding for EN
The nasogastric route should be considered in patients requiring short-term (2-4 weeks) EN. Endoscopic gastro/jejunostomy is recommended for patients requiring tube feeding for more than 4 weeks. The temperature of the EN solution should be maintained at about 40℃. Continuous infusion using an infusion pump is recommended, with a flow rate of 20-30 ml/h at the beginning. If there is no retention after 2 hour, the speed can be increased at a rate of 10 ml/h up to 60-100ml/h. The gastrointestinal feeding tube can be connected with a Hemovac drain to determine whether there is gastric retention.
Suggestions for treating intolerance of EN via a nasogastric tube include: (1) use gastrointestinal stimulants (such as metoclopramide and erythromycin) or narcotic antagonists (such as naloxone and alvimopan), (2) change to post-pyloric feeding.
To avoid aspiration-related pneumonia, it is recommended to (1) raise the head of the bed to a 30-45° angle, (2) patients at high risk of aspiration-related pneumonia or patients with positive pressure ventilation should be given the option of using a nasal jejunal tube or having endoscopic gastro/jejunostomy (PEG/J).
- Nutritional management of patients on a ventilator
It was reported that 38.7% of severe patients infected with COVID-19 infections require mechanical ventilation(1). Positive mechanical ventilation changes the normal negative pressure in the chest, which indirectly increases the intra-abdominal pressure and significantly weakens diaphragmatic breathing, especially under a high driving pressure or positive end-expiratory pressure. Therefore, nutrition therapy should be carried out step-by-step to determine each individual’s nutritional requirements. The intestinal functions should be carefully monitored until perfusion and oxygenation improves. A top-down strategy for the five-step ladder principle is recommended (PN→PPN+PEN→EN), and the water being provided should be moderately increased(102). A chlorhexidine mouthwash used twice a day can reduce the risk of ventilator-associated pneumonia(25).
At present, the COVID-19 outbreak has put tremendous pressure on the physical health, mental health and daily life in China as well as the whole world. Huge challenges have been brought to world’s economic development and social order, leading to a massive consumption of human, financial and material resources. In the absence of specific antiviral therapy, and even if/when antiviral therapy becomes available, improving the nutritional status and immunity of individuals are always the most important measures for the prevention and treatment (as well as the recovery from) infectious diseases, including COVID-19 infection. Extensive studies have confirmed that nutrition therapy can significantly improve the therapeutic effects of conventional treatments, shorten the length of stay in both the hospital and ICU, reduce mortality, improve the prognosis of patients and reduce medical costs(27, 28). According to the latest research from the American Society of Parenteral and Enteral Nutrition, nutrition therapy saves 52 million US dollars for patients with sepsis every year, and 580 million US dollars for patients with sepsis, gastrointestinal cancer, nosocomial infections, surgical complications and pancreatitis(29). Therefore, in the war against COVID-19 infection, great importance should be attached to the core position and basic role of nutritional therapy. The nutritional status should be regarded as a basic vital sign(103), and nutritional therapy should be regarded as first-line treatment(104) both for COVID-19 and for the majority of human diseases. The present CSPEN consensus on nutrition therapy for severe patients with COVID-19 infections will benefit not only China but also the whole world and will help not only fighting with COVID-19 infections at present but also other virus infection in the future.
This work was sponsored by the National Key Research and Development Program awarded to Dr. Hanping Shi (No. 2017YFC1309200).
All the authors declare no conflicts of
1.W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D. Hui, B. Du, L. Li, G. Zeng, K. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, S. Li, J. Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Y. Hu, P. Peng, J. Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, N. Zhong, Clinical characteristics of 2019 novel coronavirus infection in China.
2.Y. Yang, Q. Lu, M. Liu, Y. Wang, A. Zhang, N. Jalali, N. Dean, I. Longini, E. M. Halloran, B. Xu, X. Zhang, L. Wang, W. Liu, L. Fang, Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China.
3.N. Zhong, X. Liu, B. Wang, Y. Liu, K. Ge, W. Wu, J. Li, Z. Jiang, X. Wang, Z. Lu, D. Li, Recommendations of nutritional support for SARS patients with malnutrition. Chin J Burns 19, 225 (2003).
4.X. Liu, N. Zhong, S. Chen, W. He, Y. Li, Clinical Nutrition Support and Relationship of Blood Glucose Level/Insulin Administration with Outcome in Critically SARS Patients. Chin J ClinNutr 25, 363-367 (2003).
5.A. Willig, L. Wright, T.A. Galvin, Practice Paper of the Academy of Nutrition and Dietetics: Nutrition Intervention and Human Immunodeficiency Virus Infection. J Acad Nutr Diet 118, 486-498 (2018).
6.S. Cohen, K. Danzaki, N.J. MacIver, Nutritional effects on T-cell immunometabolism. Eur J Immunol 47, 225-235 (2017).
7.K. Yu, H. Shi, Comment on ‘Recommendations on medical nutrition therapy for patients with novel coronavirus-infected pneumonia’. Natl Med J China 100, E005 (2020).
8.J.S. Lee, J.E. Kang, S.H. Park, H.K. Jin, S.M. Jang, S.A. Kim, S.J. Rhie, Nutrition and Clinical Outcomes of Nutrition Support in Multidisciplinary Team for Critically Ill Patients. Nutr Clin Pract 33, 633-639 (2018).
9.B.C. Shin, I.A. Chun, S.Y. Ryu, J.E. Oh, P.K. Choi, H.G. Kang, Association between indication for therapy by nutrition support team and nutritional status. Medicine (Baltimore) 97, e13932 (2018).
10.A. Ukleja, K. Gilbert, K.M. Mogensen, R. Walker, C.T. Ward, J. Ybarra, B. Holcombe, Standards for Nutrition Support: Adult Hospitalized Patients. Nutr Clin Pract 33, 906-920 (2018).
11.L. Zhang, Y. Liu, Potential Interventions for Novel Coronavirus in China: A Systematic Review. J Med Virol (2020).
12.H. Shi, Q. Zhao, K. Wang, H. Xu, W. Li, Y. Fang, S. Yu, Y. Qi, G. Zhu, Q. Lu, Q. Luo, X. Zhang, R. Tan, G. Jiao, R. Jia, Z. L, G. S, C. MH, L. ZN, W. K, X. Zhang, K. Yu, Y. Liu, Y. Zhou, C. Xie, J. Cui, W. Guan, W. Shi, W. Hu, C. Zhao, W. Chen, C. Zhu, L. SY, F. Gao, Y. Ba, Z. Chen, Y. Lin, W. Cao, G. Chen, Three-level diagnosis of malnutrition. Chin J OncolPrev and Treat 7, 313-319 (2015).
13.A. Coltman, S. Peterson, K. Roehl, H. Roosevelt, D. Sowa, Use of 3 tools to assess nutrition risk in the intensive care unit. JPEN J Parenter Enteral Nutr 39, 28-33 (2015).
14.H.M. Ata Ur-Rehman, W. Ishtiaq, M. Yousaf, S. Bano, A.M. Mujahid, A. Akhtar, Modified Nutrition Risk in Critically Ill (mNUTRIC) Score to Assess Nutritional Risk in Mechanically Ventilated Patients: A Prospective Observational Study from the Pakistani Population. Cureus 10, e3786 (2018).
15.A. Mukhopadhyay, J. Henry, V. Ong, C.S. Leong, A.L. Teh, R.M. van Dam, Y. Kowitlawakul, Association of modified NUTRIC score with 28-day mortality in critically ill patients. Clin Nutr 36, 1143-1148 (2017).
16.S. Bector, K. Vagianos, M. Suh, D.R. Duerksen, Does the Subjective Global Assessment Predict Outcome in Critically Ill Medical Patients? J Intensive Care Med 31, 485-489 (2016).
17.T. Cederholm, G.L. Jensen, M. Correia, M.C. Gonzalez, R. Fukushima, T. Higashiguchi, G. Baptista, R. Barazzoni, R. Blaauw, A.J.S. Coats, A.N. Crivelli, D.C. Evans, L. Gramlich, V. Fuchs-Tarlovsky, H. Keller, L. Llido, A. Malone, K.M. Mogensen, J.E. Morley, M. Muscaritoli, I. Nyulasi, M. Pirlich, V. Pisprasert, M.A.E. de van der Schueren, S. Siltharm, P. Singer, K. Tappenden, N. Velasco, D. Waitzberg, P. Yamwong, J. Yu, A. Van Gossum, C. Compher, GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 10, 207-217 (2019).
18.J.P. Allard, H. Keller, L. Gramlich, K.N. Jeejeebhoy, M. Laporte, D.R. Duerksen, GLIM criteria has fair sensitivity and specificity for diagnosing malnutrition when using SGA as comparator. Clin Nutr (2019).
19.H. Shi, M. Cong, W. Chen, Rethinking for three-level diagnosis of malnutrition. Chinese Journal of the Frontiers of Medical Science 12, 1-7 (2020).
20.C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497-506 (2020).
21.D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang, Z. Cheng, Y. Xiong, Y. Zhao, Y. Li, X. Wang, Z. Peng, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama (2020).
22.N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Y. Qiu, J. Wang, Y. Liu, Y. Wei, J. Xia, T. Yu, X. Zhang, L. Zhang, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507-513 (2020).
23.J.Y. Kim, P.G. Choe, Y. Oh, K.J. Oh, J. Kim, S.J. Park, J.H. Park, H.K. Na, M.D. Oh, The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. J Korean Med Sci 35, e61 (2020).
24.A. Patkova, V. Joskova, E. Havel, M. Kovarik, M. Kucharova, Z. Zadak, M. Hronek, Energy, Protein, Carbohydrate, and Lipid Intakes and Their Effects on Morbidity and Mortality in Critically Ill Adult Patients: A Systematic Review. Adv Nutr 8, 624-634 (2017).
25.S.A. McClave, B.E. Taylor, R.G. Martindale, M.M. Warren, D.R. Johnson, C. Braunschweig, M.S. McCarthy, E. Davanos, T.W. Rice, G.A. Cresci, J.M. Gervasio, G.S. Sacks, P.R. Roberts, C. Compher, Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 40, 159-211 (2016).
26.P. Singer, A.R. Blaser, M.M. Berger, W. Alhazzani, P.C. Calder, M.P. Casaer, M. Hiesmayr, K. Mayer, J.C. Montejo, C. Pichard, J.C. Preiser, A.R.H. van Zanten, S. Oczkowski, W. Szczeklik, S.C. Bischoff, ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 38, 48-79 (2019).
27.T.J. Philipson, J.T. Snider, D.N. Lakdawalla, B. Stryckman, D.P. Goldman, Impact of oral nutritional supplementation on hospital outcomes. Am J Manag Care 19, 121-128 (2013).
28.P. Schuetz, R. Fehr, V. Baechli, M. Geiser, M. Deiss, F. Gomes, A. Kutz, P. Tribolet, T. Bregenzer, N. Braun, C. Hoess, V. Pavlicek, S. Schmid, S. Bilz, S. Sigrist, M. Brandle, C. Benz, C. Henzen, S. Mattmann, R. Thomann, C. Brand, J. Rutishauser, D. Aujesky, N. Rodondi, J. Donze, Z. Stanga, B. Mueller, Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. Lancet 393, 2312-2321 (2019).
29.R. Tyler, A. Barrocas, P. Guenter, K. Araujo Torres, M.L. Bechtold, L.N. Chan, B. Collier, N.A. Collins, D.C. Evans, K. Godamunne, C. Hamilton, B.J.D. Hernandez, J.M. Mirtallo, W.J. Nadeau, J. Partridge, M. Perugini, A. Valladares, Value of Nutrition Support Therapy: Impact on Clinical and Economic Outcomes in the United States. JPEN J Parenter Enteral Nutr (2020).
30.H. Shi, H. Xu, S. Li, W. Cao, W. Li, Y. Ba, G. Chen, K. Wang, Y. Qi, Z. Chen, K. Yu, H. Jiang, W. Hu, M. Cong, J. Chen, Z. Li, Y. Fang, S. Ge, X. Wang, Y. Lin, W. Guan, Q. Luo, Five-step ladder treatment for malnutrition. Electron J Metab Nutr Cancer 2, 29-33 (2015).
31.B.G. Chousterman, F.K. Swirski, G.F. Weber, Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol 39, 517-528 (2017).
32.I.A. Clark, B. Vissel, The meteorology of cytokine storms, and the clinical usefulness of this knowledge. Semin Immunopathol 39, 505-516 (2017).
33.S.K. Lau, C.C. Lau, K.H. Chan, C.P. Li, H. Chen, D.Y. Jin, J.F. Chan, P.C. Woo, K.Y. Yuen, Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 94, 2679-2690 (2013).
34.F.B. Cerra, Hypermetabolism, organ failure, and metabolic support. Surgery 101, 1-14 (1987).
35.S.J. Rugeles, J.D. Rueda, C.E. Diaz, D. Rosselli, Hyperproteic hypocaloric enteral nutrition in the critically ill patient: A randomized controlled clinical trial. Indian J Crit Care Med 17, 343-349 (2013).
36.L.J. Hoffer, High-Protein Hypocaloric Nutrition for Non-Obese Critically Ill Patients. Nutr Clin Pract 33, 325-332 (2018).
37.S.J. Rugeles, J.B. Ochoa Gautier, R.N. Dickerson, J.A. Coss-Bu, J. Wernerman, D. Paddon-Jones, How Many Nonprotein Calories Does a Critically Ill Patient Require? A Case for Hypocaloric Nutrition in the Critically Ill Patient. Nutr Clin Pract 32, 72s-76s (2017).
38.H. Nicastro, C.R. da Luz, D.F. Chaves, L.R. Bechara, V.A. Voltarelli, M.M. Rogero, A.H. Lancha, Jr., Does Branched-Chain Amino Acids Supplementation Modulate Skeletal Muscle Remodeling through Inflammation Modulation? Possible Mechanisms of Action. J Nutr Metab 2012, 136937 (2012).
39.A. Ocana-Mondragon, J.A. Mata-Marin, M. Uriarte-Lopez, C. Bekker-Mendez, E. Alcala-Martinez, R.M. Ribas-Aparicio, L.A. Uribe-Noguez, D.M. Rodriguez-Galindo, M.L. Martinez-Rodriguez, Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients. Biomed Rep 8, 85-90 (2018).
40.Y. Nagao, T. Kawaguchi, T. Ide, M. Sata, Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. Virol J 9, 282 (2012).
41.L. Pradelli, K. Mayer, M. Muscaritoli, A.R. Heller, n-3 fatty acid-enriched parenteral nutrition regimens in elective surgical and ICU patients: a meta-analysis. Crit Care 16, R184 (2012).
42.Y. Wang, H. Lin, B.W. Lin, J.D. Lin, Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis. Ann Intensive Care 9, 58 (2019).
43.M.G. Kashiouris, M. L’Heureux, C.A. Cable, B.J. Fisher, S.W. Leichtle, A.A.F. Iii, The Emerging Role of Vitamin C as a Treatment for Sepsis. Nutrients 12, (2020).
44.A.A. Fowler Iii, C. Kim, L. Lepler, R. Malhotra, O. Debesa, R. Natarajan, B.J. Fisher, A. Syed, C. DeWilde, A. Priday, V. Kasirajan, Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome. World J Crit Care Med 6, 85-90 (2017).
45.J.K. Sun, W.H. Zhang, W.X. Chen, X. Wang, X.W. Mu, Effects of early enteral nutrition on Th17/Treg cells and IL-23/IL-17 in septic patients. World J Gastroenterol 25, 2799-2808 (2019).
46.A. Reintam Blaser, J. Starkopf, W. Alhazzani, M.M. Berger, M.P. Casaer, A.M. Deane, S. Fruhwald, M. Hiesmayr, C. Ichai, S.M. Jakob, C.I. Loudet, M.L. Malbrain, J.C. Montejo Gonzalez, C. Paugam-Burtz, M. Poeze, J.C. Preiser, P. Singer, A.R. van Zanten, J. De Waele, J. Wendon, J. Wernerman, T. Whitehouse, A. Wilmer, H.M. Oudemans-van Straaten, Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med 43, 380-398 (2017).
47.P. Feng, C. He, G. Liao, Y. Chen, Early enteral nutrition versus delayed enteral nutrition in acute pancreatitis: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 96, e8648 (2017).
48.D. Qi, B. Yu, J. Huang, M. Peng, Meta-Analysis of Early Enteral Nutrition Provided Within 24 Hours of Admission on Clinical Outcomes in Acute Pancreatitis. JPEN J Parenter Enteral Nutr 42, 1139-1147 (2018).
49.C.A.C. Association, Guidelines for oral nutrition supplement. Electron J Metab Nutr Cancer 2, 33-34 (2015).
50.N. Lin, J. Shi, Y. Chen, H. Shi, Basic issues of oral nutritional supplements. Electron J Metab Nutr Cancer 2, 5-9 (2015).
51.D.K. Heyland, R. Dhaliwal, M. Wang, A.G. Day, The prevalence of iatrogenic underfeeding in the nutritionally ‘at-risk’ critically ill patient: Results of an international, multicenter, prospective study. Clin Nutr 34, 659-666 (2015).
52.S. Villet, R.L. Chiolero, M.D. Bollmann, J.P. Revelly, R.N.M. Cayeux, J. Delarue, M.M. Berger, Negative impact of hypocaloric feeding and energy balance on clinical outcome in ICU patients. Clin Nutr 24, 502-509 (2005).
53.S.R. Lewis, O.J. Schofield-Robinson, P. Alderson, A.F. Smith, Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for adults in the intensive care unit. Cochrane Database Syst Rev 6, Cd012276 (2018).
54.J.P. Nurkkala, T.I. Kaakinen, M.A. Vakkala, T.I. Ala-Kokko, J.H. Liisanantti, Nutrition deficit during intensive care stay: incidence, predisposing factors and outcomes. Minerva Anestesiol (2020).
55.T. Oshima, C. Pichard, Parenteral nutrition: never say never. Crit Care 19 Suppl 3, S5 (2015).
56.C.P. Heidegger, M.M. Berger, S. Graf, W. Zingg, P. Darmon, M.C. Costanza, R. Thibault, C. Pichard, Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet 381, 385-393 (2013).
57.L. Pradelli, S. Graf, C. Pichard, M.M. Berger, Supplemental parenteral nutrition in intensive care patients: A cost saving strategy. Clin Nutr 37, 573-579 (2018).
58.E.J. Ridley, A.R. Davies, R. Parke, M. Bailey, C. McArthur, L. Gillanders, D.J. Cooper, S. McGuinness, Supplemental parenteral nutrition versus usual care in critically ill adults: a pilot randomized controlled study. Crit Care 22, 12 (2018).
59.P.E. Wischmeyer, M. Hasselmann, C. Kummerlen, R. Kozar, D.J. Kutsogiannis, C.J. Karvellas, B. Besecker, D.K. Evans, J.C. Preiser, L. Gramlich, K. Jeejeebhoy, R. Dhaliwal, X. Jiang, A.G. Day, D.K. Heyland, A randomized trial of supplemental parenteral nutrition in underweight and overweight critically ill patients: the TOP-UP pilot trial. Crit Care 21, 142 (2017).
60.J. Yu, G. Wu, Y. Tang, Y. Ye, Z. Zhang, Efficacy, Safety, and Preparation of Standardized Parenteral Nutrition Regimens: Three-Chamber Bags vs Compounded Monobags-A Prospective, Multicenter, Randomized, Single-Blind Clinical Trial. Nutr Clin Pract 32, 545-551 (2017).
61.D. Berlana, M.A. Almendral, M.R. Abad, A. Fernandez, A. Torralba, M. Cervera-Peris, G. Pineiro, R. Romero-Jimenez, A. Vazquez, E. Ramirez, M. Yebenes, A. Munoz, Cost, Time, and Error Assessment During Preparation of Parenteral Nutrition: Multichamber Bags Versus Hospital-Compounded Bags. JPEN J Parenter Enteral Nutr 43, 557-565 (2019).
62.M.M. Berger, N. Achamrah, C. Pichard, Parenteral nutrition in intensive care patients: medicoeconomic aspects. Curr Opin Clin Nutr Metab Care 21, 223-227 (2018).
63.A. Weimann, M. Braga, F. Carli, T. Higashiguchi, M. Hubner, S. Klek, A. Laviano, O. Ljungqvist, D.N. Lobo, R. Martindale, D.L. Waitzberg, S.C. Bischoff, P. Singer, ESPEN guideline: Clinical nutrition in surgery. Clin Nutr 36, 623-650 (2017).
64.S.A. McClave, C.C. Lowen, M.J. Kleber, J.F. Nicholson, S.C. Jimmerson, J.W. McConnell, L.Y. Jung, Are patients fed appropriately according to their caloric requirements? JPEN J Parenter Enteral Nutr 22, 375-381 (1998).
65.S. Honeywell, R. Zelig, D. Rigassio Radler, Impact of Intravenous Lipid Emulsions Containing Fish Oil on Clinical Outcomes in Critically Ill Surgical Patients: A Literature Review. Nutr Clin Pract 34, 112-122 (2019).
66.P.C. Calder, Intravenous Lipid Emulsions to Deliver Bioactive Omega-3 Fatty Acids for Improved Patient Outcomes. Mar Drugs 17, (2019).
67.L. Pradelli, M. Muscaritoli, S. Klek, R.G. Martindale, Pharmacoeconomics of Parenteral Nutrition with omega-3 Fatty Acids in Hospitalized Adults. JPEN J Parenter Enteral Nutr 44 Suppl 1, S68-S73 (2020).
68.K.G. Kreymann, D.K. Heyland, G. de Heer, G. Elke, Intravenous fish oil in critically ill and surgical patients – Historical remarks and critical appraisal. Clin Nutr 37, 1075-1081 (2018).
69.M.A. Baker, B.S. Cho, L. Anez-Bustillos, D.T. Dao, A. Pan, A.A. O’Loughlin, Z.M. Lans, P.D. Mitchell, V. Nose, K.M. Gura, M. Puder, G.L. Fell, Fish oil-based injectable lipid emulsions containing medium-chain triglycerides or added alpha-tocopherol offer anti-inflammatory benefits in a murine model of parenteral nutrition-induced liver injury. Am J Clin Nutr 109, 1038-1050 (2019).
70.E.D. Olthof, H.M. Roelofs, M.W. Versleijen, R.H. Te Morsche, E.R. Simonetti, P.W. Hermans, G.J. Wanten, Long-term olive oil-based parenteral nutrition sustains innate immune function in home patients without active underlying disease. Clin Nutr 32, 643-649 (2013).
71.C. Gao, M. Li, J. Wei, Y. Li, W. Tian, H. Jiang, W. Shen, A. Xu, Z. Yu, D. Chen, L. Chen, W. Guan, H. Jiang, L. DK, D. Mei, J. Yu, C. Zhao, W. Fan, S. Hu, Y. Kang, W. Kang, C. Lv, D. Liu, H. Liu, Y. Lv, X. Meng, J. Song, M. Sun, Q. Tang, L. Wang, J. Wang, D. Wu, Y. Xu, H. Xu, W. Yan, X. Yan, J. Zeng, P. Zhang, J. Gong, Z. Guo, J. Hu, Q. Meng, Z. Li, S. Qian, B. Qin, S. Shen, H. Xu, Y. Yao, L. Yu, H. Shi, Expert consensus on clinical use of compound amino acid injection. Electron J Metab Nutr Cancer 6, 183-189 (2019).
72.H. Shi, Tumor is a metabolic disease. Electron J Metab Nutr Cancer 5, 111-116 (2018).
73.K. Lach, S.J. Peterson, Nutrition Support for Critically Ill Patients With Cancer. Nutr Clin Pract 32, 578-586 (2017).
74.R.D. Griffiths, Specialized nutrition support in the critically ill: for whom and when? Nestle Nutr Workshop Ser Clin Perform Programme 7, 199-214; discussion 214-197 (2002).
75.M.G. Annetta, M. Pittiruti, P. Vecchiarelli, D. Silvestri, A. Caricato, M. Antonelli, Immunonutrients in critically ill patients: an analysis of the most recent literature. Minerva Anestesiol 82, 320-331 (2016).
76.D.C. Evans, R.A. Hegazi, Immunonutrition in Critically Ill Patients: Does One Size Fit All? JPEN J Parenter Enteral Nutr 39, 500-501 (2015).
77.T.W. Rice, Immunonutrition in critical illness: limited benefit, potential harm. Jama 312, 490-491 (2014).
78.J. Sun, J. Zhang, C. Chang, H. Zhu, C. Huang, W. Cao, Y. Jiang, G. He, B. Mo, P. Fu, K. Yu, W. Chen, Expert consensus on nutrition and exercise intervention for sarcopenia. ActaNutrimentaSinica 37, 320-324 (2015).
79.C.F.A. Silva, S.G. de Vasconcelos, T.A. da Silva, F.M. Silva, Permissive or Trophic Enteral Nutrition and Full Enteral Nutrition Had Similar Effects on Clinical Outcomes in Intensive Care: A Systematic Review of Randomized Clinical Trials. Nutr Clin Pract 33, 388-396 (2018).
80.O. Stuani Franzosi, A. Delfino von Frankenberg, S.H. Loss, D. Silva Leite Nunes, S.R. Rios Vieira, Underfeeding versus full enteral feeding in critically ill patients with acute respiratory failure: a systematic review with meta-analysis of randomized controlled trials. Nutr Hosp 34, 19-29 (2017).
81.J.J. Patel, M. Kozeniecki, A. Biesboer, W. Peppard, A.S. Ray, S. Thomas, E.R. Jacobs, R. Nanchal, G. Kumar, Early Trophic Enteral Nutrition Is Associated With Improved Outcomes in Mechanically Ventilated Patients With Septic Shock: A Retrospective Review. J Intensive Care Med 31, 471-477 (2016).
82.A. De Lorenzo, M.L. Petroni, S. Masala, G. Melchiorri, M. Pietrantuono, G. Perriello, A. Andreoli, Effect of acute and chronic branched-chain amino acids on energy metabolism and muscle performance. Diabetes Nutr Metab 16, 291-297 (2003).
83.P.L. Langlois, F. D’Aragon, G. Hardy, W. Manzanares, Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: A systematic review and meta-analysis. Nutrition 61, 84-92 (2019).
84.Y. Liu, Y. Yang, C. Zhang, F. Huang, F. Wang, J. Yuan, Z. Wang, J. Li, J. Li, C. Feng, Z. Zhang, L. Wang, L. Peng, L. Chen, Y. Qin, D. Zhao, S. Tan, L. Yi, J. Xu, C. Zhou, C. Jiang, L. Liu, Clinical and biochemical indicators related to lung injury in patients with novel coronavirus (2019-nCoV) infection. ScientiaSinica(Vitae). http://kns.cnki.net/kcms/detail/11.5840.Q.20200212.0801.006.html.
85.S. Kim, S.A. McClave, R.G. Martindale, K.R. Miller, R.T. Hurt, Hypoalbuminemia and Clinical Outcomes: What is the Mechanism behind the Relationship? Am Surg 83, 1220-1227 (2017).
86.M. Ulldemolins, J.A. Roberts, J. Rello, D.L. Paterson, J. Lipman, The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 50, 99-110 (2011).
87.H. T’Jollyn, A. Vermeulen, J. Van Bocxlaer, P. Colin, A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients. Clin Pharmacokinet 57, 59-69 (2018).
88.A. Gatta, A. Verardo, M. Bolognesi, Hypoalbuminemia. Intern Emerg Med 7 Suppl 3, S193-199 (2012).
89.B.J. Conner, Treating Hypoalbuminemia. Vet Clin North Am Small Anim Pract 47, 451-459 (2017).
90.A. Qaseem, R. Chou, L.L. Humphrey, P. Shekelle, Inpatient glycemic control: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Am J Med Qual 29, 95-98 (2014).
91.W.C. Chao, C.H. Tseng, C.L. Wu, S.J. Shih, C.Y. Yi, M.C. Chan, Higher glycemic variability within the first day of ICU admission is associated with increased 30-day mortality in ICU patients with sepsis. Ann Intensive Care 10, 17 (2020).
92.S. Lv, P. Ross, K. Tori, The optimal blood glucose level for critically ill adult patients. Nurs Crit Care 22, 312-319 (2017).
93.M.K. Sechterberger, R.J. Bosman, H.M. Oudemans-van Straaten, S.E. Siegelaar, J. Hermanides, J.B. Hoekstra, J.H. De Vries, The effect of diabetes mellitus on the association between measures of glycaemic control and ICU mortality: a retrospective cohort study. Crit Care 17, R52 (2013).
94.K. Briggs Early, K. Stanley, Position of the Academy of Nutrition and Dietetics: The Role of Medical Nutrition Therapy and Registered Dietitian Nutritionists in the Prevention and Treatment of Prediabetes and Type 2 Diabetes. J Acad Nutr Diet 118, 343-353 (2018).
95.X. Qin, Y. Li, N. Sun, H. Wang, Y. Zhang, J. Wang, J. Li, X. Xu, M. Liang, J. Nie, B. Wang, X. Cheng, N. Li, Y. Sun, L. Zhao, X. Wang, F.F. Hou, Y. Huo, Elevated Homocysteine Concentrations Decrease the Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitors in Hypertensive Patients. Arterioscler Thromb Vasc Biol 37, 166-172 (2017).
96.S.L. Lennon, D.M. DellaValle, S.G. Rodder, M. Prest, R.C. Sinley, M.K. Hoy, C. Papoutsakis, 2015 Evidence Analysis Library Evidence-Based Nutrition Practice Guideline for the Management of Hypertension in Adults. J Acad Nutr Diet 117, 1445-1458.e1417 (2017).
97.C. Ozemek, D.R. Laddu, R. Arena, C.J. Lavie, The role of diet for prevention and management of hypertension. Curr Opin Cardiol 33, 388-393 (2018).
98.N. Buetti, J.F. Timsit, Management and Prevention of Central Venous Catheter-Related Infections in the ICU. Semin Respir Crit Care Med 40, 508-523 (2019).
99.C. Chernecky, D. Macklin, P. Blackburn, Catheter-Related Bloodstream Infections (CR-BSI) in Geriatric Patients in Intensive Care Units. Crit Care Nurs Q 38, 280-292 (2015).
100.R.S. Turpin, T. Canada, F.X. Liu, C.J. Mercaldi, A. Pontes-Arruda, P. Wischmeyer, Nutrition therapy cost analysis in the US: pre-mixed multi-chamber bag vs compounded parenteral nutrition. Appl Health Econ Health Policy 9, 281-292 (2011).
101.M. Bekcibasi, S. Dayan, E. Aslan, M.Z. Kortak, S. Hosoglu, Risk factors for central venous catheter-related bloodstream infections. Infez Med 27, 258-265 (2019).
102.Y. An, Nutritional support during mechanicl ventilation. Chin J RespCrit Care 3, 139-141 (2004).
103.K. Yu, L. Liu, H. Shi, Nutritional status: a basic ‘vital sign’. Electron J Metab Nutr Cancer 6, 391-395 (2019).
104.H. Shi, Nutrition therapy is the first-line treatment for tumors. Clin Med J 17, 20-25 (2019).